Tracheostomy Products Market - Global Industry Trends & Future Forecasts

Overview of This Study:

The study involved four major activities in estimating the current size of the Tracheostomy Surgery Market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Geographical Growth Scenario:

North America is the largest regional market for tracheostomy products market

North America is one of the major revenue-generating regions in the market. The presence of a highly developed healthcare system, increasing number of emergency department visits, high adoption of innovative tracheostomy devices among medical professionals, wide availability of advanced tracheostomy devices, the large number of tracheostomy devices manufacturing companies that have an established base, and the rising prevalence of chronic respiratory diseases are driving the growth of the tracheostomy products industry in North America.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=79626751

Recent Developments in the Global Tracheostomy Surgery Market:

# In February 2019, Medtronic Plc entered into a partnership with Medical University of South Carolina (US) for the development of better and affordable healthcare solutions (including tracheostomy procedure for breathing assistance) for patients

# In October 2017, Medtronic Plc established the Chengdu Innovation Center at Singapore for cross-disciplinary clinical training and R&D.

Hospitals & surgical centers segment accounted for the largest share of the tracheostomy products market, by the end-user, in 2018

Hospitals & surgical centers were the largest application segment of the tracheostomy products industry, and this trend is expected to continue during the forecast period. A large number of private enterprises are taking steps to cater to the needs of modern, which has resulted in the large share of this segment. Other significant factors include well-equipped state-run healthcare facilities in these regions and growing healthcare consolidation to improve access to healthcare services.

Key Questions Addressed by the Report:

# Emerging countries are offering immense opportunities for the growth and adoption of market. Will this scenario continue in the coming years?
# Where will all the advancements in products offered by various companies take the industry in the mid-to-long term?
# What are the various research institutes where tracheostomy products find a high adoption rate?
# What are the new trends and advancements in the market?
# How is the shift in dynamics shaping the future of the market?

Expected Revenue Growth:

The tracheostomy products market size is projected to reach USD 220 million by 2024 from USD 179 million in 2019, at a CAGR of 4.2% during the forecast period. Growth in the tracheostomy products industry is driven primarily by the growing public awareness related to tracheostomy procedures among medical professionals, increasing prevalence of respiratory diseases & disorders, and availability of medical reimbursement and insurance coverage.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=79626751

Key Market Players:

Medtronic plc (Ireland), Smiths Group plc (UK), TRACOE Medical GmbH (Germany), Teleflex Incorporated (US), and Fisher & Paykel Healthcare Ltd. (New Zealand) were the top five players in the global tracheostomy products market.

Other prominent players operating in Tracheostomy Surgery Market include ConvaTec Group (US), Cook Group (US), Troge Medical GmbH (Germany), Well Lead Medical Co., Ltd. (US), Fuji Systems Corporation (Japan), Andreas Fahl Medizintechnik-Vertrieb GmbH (Germany), Xinxiang Huaxi Sanitary Materials Co., Ltd. (China), Medis Medical (Tianjin) Co. Ltd. (China), Boston Medical (US), and Pulmodyne (US), among others.

Bioprocess Validation Market - Increasing Demand for Outsourcing Bioprocess Validation

Overview of This Study:

This study involved the extensive use of primary and secondary sources and involved an in-depth analysis of the various factors affecting the growth of the global Bioprocess Validation Research Technique Market. Both primary and secondary research was used to identify the segmentation types, trends, key players, key market dynamics, and key player strategies as well as derive the competitive leadership mapping and competitive landscape in this market.

Expected Revenue Growth:

The global bioprocess validation market is exceeded USD 180 million in 2019 and is projected to be valued over USD 360 million by 2024, at a CAGR of 14.6% during the forecast period.

Global Growth Boosting Factors:

Stringent safety and quality regulations governing product certification and testing across the biopharmaceutical and pharmaceutical industries, high demand for the outsourcing of bioprocess validation services, and regulatory mandates in the healthcare industry to maintain compliance with Good Manufacturing Practices (GMP) are the major factors driving the growth of this market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39981433

Objectives of the Study:

# To define, describe, and forecast the Bioprocess Validation Research Technique Market based on test type, process component, end-user, and region.

# To provide detailed information regarding the factors influencing market growth (such as drivers, restraints, opportunities, challenges, and industry trends)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall bioprocess validation services market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players operating in this market.

# To strategically profile the key players in the bioprocess validation services market and comprehensively analyze their market shares and core competencies

# To strategically analyze five different geographical regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

# To track and analyze competitive developments such as joint ventures & acquisitions; product developments and enhancements; agreements & partnerships; expansions; and funding activities in the bioprocess validation market.

End Users:

Contract Development and Manufacturing Organizations (CDMOs) to form the fastest-growing end-user segment in the bioprocess validation market

Among all end-user segments, the demand for bioprocess validation is estimated to grow at the highest rate among CDMOs. This can majorly be attributed to the stringent FDA safety regulations and consumer lawsuits regarding testing requirement, accelerating costs of validation and quality check processes after or during drug development, increasing adoption of bioprocess validation services to keep biopharma production, and approvals in line with the regulatory requirements.

Geographical Growth Scenario:

North America is estimated to be the largest regional market for bioprocess validation

North America is expected to account for the largest share of the Bioprocess Validation Research Technique Market in 2019, closely followed by Europe. Factors such as the presence of well-established biopharmaceutical industry in the region, high R&D expenditure, presence of leading bioprocess validation service providers, and stringent regulatory requirements for biopharmaceutical production are driving the growth of the bioprocess validation market in North America.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=39981433

Global Leaders:

The prominent players operating in the bioprocess validation market are Merck KGaA (Germany), Sartorius Stedim Biotech (Sartorius AG) (France), Pall Corporation (US), SGS S.A. (Switzerland), Eurofins Scientific (Luxembourg), Cobetter Filtration Equipment Co., Ltd. (China), Toxikon Corporation (US), DOC S.r.l. (Italy), MEISSNER FILTRATION PRODUCTS, INC. (US), and Thermo Fisher Scientific (US).

Animal Parasiticides Market - Expected Revenue Growth in Near Future

Overview of This Study:

The study involved four major activities for estimating the size of the animal parasiticides market. Exhaustive secondary research was done to collect information on the market, including its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Expected Revenue Growth:

The global animal parasiticides market is projected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2 % during the forecast period. Market growth can be attributed to the growing population of companion animals, rising demand for animal-derived food products, growing concerns of zoonotic diseases, rising animal pet expenditure, and increasing investments from private players.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258895412

North America will continue to dominate the market during the forecast period

Geographically, the global animal parasiticides market has been segmented into five major regional segments—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the market in 2019, followed by Europe and the Asia Pacific. North America’s leading position is primarily due to the rising pet expenditure, the growing population of companion animals, and the increasing consumption of animal-derived food products.

Key Market Players:

The prominent players in the global Animal parasiticides market are Boehringer Ingelheim (Germany), Elanco (US), Zoetis (US), Merck (US), and Virbac (France).

Recent Developments in the Global Animal Parasiticides Market:

# In February 2020, Zoetis launched Simparica Trio, a parasiticide for dogs with, or at risk from, mixed external and internal parasitic infestations.

# In February 2020, Elanco signed an agreement with Merck Animal Health to divest its worldwide rights for Vecoxan, used for the prevention and treatment of coccidiosis in calves and lambs.

# In February 2020, Vetoquinol acquired rights to Profendor and Drontal (parasiticides for companion animals offered by Elanco) for the European Economic Area and the UK.

# In August 2019, Boehringer Ingelheim opened a Health Management Center in China.

Key Questions Addressed in the Report

# Which are the top 10 players operating in the animal parasiticides market?
# What are the drivers, restraints, opportunities, and challenges impacting the market?
# What are the prevailing industry trends?
# What is the current scenario of the animal parasiticides market?
# How is the animal parasiticides market performing in different regions across the globe?

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=258895412

Research Methodology Followed:

Top-down and bottom-up approaches were used to validate the size of the global animal parasiticides market and dependent submarkets. Various secondary sources such as directories, industry journals, databases, and annual reports of companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both the supply and demand sides have been interviewed to obtain and validate information as well as assess the dynamics of this market.

Target Audience:

# Veterinary hospitals and clinics
# Veterinary research institutes
# Animal health companies
# Animal farms
# Government associations
# Market research and consulting firms
# Venture capitalists and investors

Healthcare Cloud Computing Market - Impact of COVID19 & Emergence of the Telecloud

Overview of This Study:

This study involved the four major activities in estimating the size of the healthcare cloud computing market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Market Size Estimation:

For the calculation of the market value, the revenue from providers was arrived at, based on the adoption rate and average expenditure on software and services in the healthcare cloud computing market. This process involved the following steps:

# Generating a list of the number of providers (hospitals, small group practices, and independent PCPs, etc.) adopting healthcare cloud computing solutions in the given year.

# Understanding the yearly average of expenditure undertaken by the various types of providers for these solutions.

# Totaling the yearly revenue to arrive at the overall market size.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=347

Expected Revenue Growth:

The market for healthcare cloud computing is expected to grow from USD 28.1 billion in 2020 to USD 64.7 billion by 2025, at a CAGR of 18.1% during the forecast period. Growth in the healthcare cloud computing market can be attributed to factors such as technological upgradation in healthcare industry, increasing focus on healthcare digitization and increasing deployment of cloud-based HCIT solutions by healthcare providers to improve the care process.

COVID-19 Impact on the Healthcare Cloud Computing Market

The COVID-19 outbreak, has upended many lives and businesses on an unprecedented scale. However, if there is one sector that has emerged stronger from this event, it would be the cloud computing industry. While many organizations are finding it difficult to run smoothly, the companies that opted for cloud computing infrastructure are functioning well.

Cloud computing assists in hassle-free data storage and backup because of its scalability, and also enables one to scale back during hectic days. Moreover, the social distancing measures have mandated patients with mild symptoms to opt for remote consultation. With many healthcare providers giving consultation over video conferencing and phone calls, in place of this pandemic, the growth of healthcare cloud computing market is likely to augment considerably over the forecast period.

Drivers: Increasing adoption of big data analytics, wearable devices, and IoT in healthcare

Healthcare providers generate and collect a large amount of data from a vast array of internal sources, such as electronic health records (EHRs), radiology images, pharmacy sales, prescription information, lab tests, and insurance claims data. The volume of this digital data is growing exponentially every year, majorly due to changes in the payer environment, such as incentives for the meaningful use of EHRs and a shift towards value-based payments. The effective management of a large volume of data requires significant computing power and IT bandwidth.

In the on-premise storage of data, healthcare providers are required to invest more in IT infrastructure with an increase in data load. As a result, on-premise storage is not considered as a viable option for the storage of a large volume of healthcare data. Cloud computing, on the other hand, enables all big data operations through the provision of large storage and processing power. Additionally, cloud-based analytical tools help providers better manage patients by transforming health data into actionable insights.

Restrains: Data security and privacy concerns

A major concern related to cloud solutions is that the data hosted by vendors is not as secure as data stored on-premise. Patient information is considered sensitive, and a high degree of privacy needs to be maintained so that this information is accessible to authorized users only. Though the cloud offers various benefits and security measures, the data stored on the cloud is still prone to cyber-attacks. With the increasing volume of patient data and rising initiatives towards digital transformation in healthcare, data security and privacy concerns are increasing rapidly.

Moreover, patients themselves are concerned about the security of their data, which adds to the necessity of maintaining security standards for data protection. Public clouds face similar security issues as traditional IT systems and are thus not preferred. Although private clouds offer more secure access protocols and systems, the healthcare industry is still skeptical about the data security of a private cloud.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=347

Asia Pacific to emerge as a potential market for healthcare cloud computing solutions

The global healthcare cloud computing market has been categorized on the basis of four major regional segments—North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is expected to grow at the highest CAGR during the forecast period. The changing demographics in highly populous countries such as China and India, large volumes of patient data generated as a result of the growing disease burden in the region and various government initiatives focusing on healthcare digitization are driving the growth of the healthcare cloud computing market in the Asia Pacific.

In addition, the current outbreak of COVID-19 in the region has resulted in the increased patient pool, leading to subsequent increase in telehealth and virtual care delivery options. Increasing investments for modernization of the country’s healthcare infrastructure is thus, expected to fuel the growth of the healthcare cloud computing market in the APAC region.

Market Key Players:

IBM (US), athenahealth (US), Siemens Healthineers (Germany), Koninklijke Philips NV (Netherlands), Allscripts Healthcare Solutions (US), Fujifilm Holdings (Japan), GE Healthcare (US), are some of the leading players of the healthcare cloud computing market.

Surgical Snare Market - Emerging Trends & Global Key Players

Overview of This Study:

The study involved 4 major activities in estimating the current size for surgical snare market. Exhaustive secondary research was done to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research:

In the secondary research process, various secondary sources such as Hoovers, Bloomberg BusinessWeek, Forbes, and Dun & Bradstreet have been referred to, so as to identify and collect information useful for a technical, market-oriented, and commercial study of the surgical snares market. These secondary sources included annual reports, press releases & investor presentations of companies, Bio-Process Systems Alliance (BPSA), BioProcess International, National Center for Biotechnology Information (NCBI), International Society for Pharmaceutical Engineering (ISPE), World Intellectual Property Organization (WIPO), and Life Science Leader Journal.

Primary Research:

The surgical snare market comprises several stakeholders such as raw material suppliers, manufacturers of surgical snare, and regulatory organizations in the supply chain. The demand side of this market is characterized by consumers of surgical snares. The supply side is characterized by surgical snare manufacturers. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=109649493

Expected Revenue Growth:

The surgical snare market is expected to grow from USD 992 million in 2018 to USD 1,255 million by 2023, at a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period. The major driving factors in the surgical snares market are increasing number for colon polypectomy procedures, growth of the endoscopic ambulatory surgical centers, and a rising preference for minimally invasive surgeries are the key factors.

Market Size Estimation:

Both the top-down and bottom-up approaches were used to estimate and validate the total size of the surgical snares market. These approaches were also used extensively to estimate the size of various sub-segments in the market. The research methodology used to estimate the market size includes the following:

# The key players have been identified through extensive secondary research

# The surgical snares industry’s value chain and market size, in terms of value have been determined through primary and secondary research.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

# All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to obtain the final quantitative and qualitative data.

End Users:

The hospital segment, by end user, is projected to occupy the majority of the market share and grow at the fastest rate during the forecast period.

Based on end user, the surgical snare market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment is expected to dominate the market in 2018. The large share and high growth rate of the hospitals segment can be attributed to increasing government and private funding, availability of highly skilled healthcare professionals, and technologically advanced facilities.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=109649493

Global Key Players:

The major surgical snares vendors include Olympus (Japan), Boston Scientific (US), Cook Medical (US), CONMED Corporation (US), Medline Industries (US), Medtronic (Ireland), Steris (US), Merit Medical Systems (US), and Avalign Technologies (US).

These players have adopted various growth strategies such as acquisitions, new product launches and approval, expansions, to expand their presence in the global surgical snares market. These strategies adopted by major players from 2015 to 2018. This has helped them to innovate their offerings and broaden their customer base.

Rheometer & Viscometer Market - Major Revenue Growth is Expected in Near Future

Overview of This Study:

This research study involves the extensive usage of secondary sources, directories, and databases [such as World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), World Bank, the European Chemical Industry Council, US Energy Information Administration, US Department of Energy, American Chemistry Council, US Census Bureau, Federal Ministry of Economic Affairs and Energy (Germany), Department of Petroleum Engineering and Applied Geophysics (Germany), Medicines & Healthcare Products Regulatory Agency (UK), and Food & Drink Sector Council (UK)], in order to identify and collect information useful for this technical, market-oriented, and financial study of the rheometer and viscometer market.

In-depth interviews were conducted with various primary respondents, including subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify qualitative and quantitative information and to assess market prospects.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93584044

Future Revenue Growth Prospects:

The global viscometer market is projected to reach USD 878.6 million by 2023 from USD 721.5 million in 2018, at a CAGR of 4.0%.

Major Growth Boosters:

The demand for rheometers and viscometers across key markets is majorly driven by factors such as technology advancements; expansion of petrochemical and material manufacturing industries; growing stringency of the regulatory framework for product safety compliance in cosmeceutical, biotechnology, and pharmaceutical industries; rising public-private investments to support product innovation; and increasing burden of target diseases, globally.

Global Industry Segmentation:

This report broadly segments the rheometer and viscometer market into product, sample type, end user, and region. On the basis of product, the viscometer market is segmented into rheometers and viscometers. The viscometers segment is expected to account for the largest share of the global rheometer market in 2018.

The large share of this segment is attributed to the increasing adoption of viscometers among lab technicians and researchers in pharmaceutical and petrochemical industries due to the procedural benefits offered by these instruments, such as the capability to analyze samples in varied environments, high accuracy, versatility for analyzing different samples, ease of handling, fast processing time, device portability, need of small sample volume, capability to analyze time-dependent fluids, and capability to perform shear-dependent analysis at various speeds.

Based on sample type, the Viscometer Market is categorized into resins & coatings, suspensions & slurries, pastes & gels, and other samples. The resins & coatings segment is expected to be the fastest-growing sample segment during the forecast period. The dominant market position of this segment is mainly due to the growing adoption of rheometers & viscometers by paint and coating manufacturers; the increasing production of paints, coatings, binders, solvents, pigments, fillers and additives; increasing usage of rheometers and viscometers among petrochemical manufacturers; and growing availability of innovative and affordable devices across emerging countries.

End Users:

On the basis of end user, the viscometer market is segmented into petroleum product manufacturers & petrochemical refineries; pharmaceutical, cosmeceutical, and biotechnology companies; chemical and material manufacturers; food and beverage manufacturers; and research & academia, and other end users. The petroleum product manufacturers & petrochemical refineries segment is expected to account for the highest growth rate of the rheometer and viscometer market during the forecast period. The high growth can be attributed to the rising production output & capabilities of major product manufacturers.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=93584044

Geographical Growth Scenario:

This report covers the market across four major regions, namely, North America, Europe, the Asia Pacific, and the RoW. North America is expected to command the largest share of the market in 2018.

Dominant position of North America in the global viscometer market is attributed to the ongoing technological advancements in the field of rheometers and viscometers, growing number of disease diagnostic procedures based on viscosity/rheology analysis, strong presence of major device manufacturers, and the wide availability of rheometers and viscometers in the region (owing to the strong distribution networks of major product manufacturers in North America).

Global Leaders:

The major players in the market are Brookfield Engineering Laboratories (US), Anton Paar (Austria), Spectris (UK), Waters Corporation (US), and Cannon Instrument Company.

Human Microbiome Market - Emerging Trends to Boost Global Revenue

Human Microbiome Market Dynamics

Driver: Increasing focus on human microbiome therapeutics development

Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.

In the last decade, microbiome therapy has gained widespread importance. During a 10-year timespan (fiscal years 2007–2016), the National Institutes of Health (NIH) invested USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP over fiscal years 2012–2016. Similarly, the European Commission established Metagenomics of the Human Intestinal Tract project (MetaHIT), which is mainly focused on gut bacteria.

Revenue Growth Dynamics:

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Restraints: Barriers in proving the causal link between dysbiosis and diseases

The human body is home to a diverse community of symbiotic, commensal, and pathogenic microorganisms, collectively known as the microbiota. Various studies also suggested that that only 30-40 species as the bulk of microbiota are shared among individuals. Analyzing specific bacteria from among trillions of species can be a highly challenging task. High-throughput omics technologies can identify the exact bacterial species involved and provide an understanding of how homeostasis between humans and microbes is maintained. According to human microbiome research, dysbiosis of microbiomes results in some of the most chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.

The current approaches for identifying microbial markers for diagnostic purposes need to rely on comparisons with parallel control groups of healthy individuals. Selecting the correct microbial chassis for a microbiota-based therapeutic is challenging, as it is difficult to predict which microbe is best suited for any given application.

Recent Developments:

# In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

# In  2020, BiomX collaborated with Boehringer Ingelheim to utilize the microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in Inflammatory Bowel Disease (IBD).

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds

By technology, the genomics segment is expected to grow at the highest CAGR during the forecast period.

On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to register the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market.

North America accounted for the largest share of the human microbiome market.

In 2019, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research & clinical activities are responsible for driving the growth of the market in North America

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Key Players:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).